NEXTBIO CAPITAL MANAGEMENT LP
Q1 2026 Form 13-F
MENLO PARK, DELAWARE
CIK 0002038158
· Institutional investment manager
$215.4M Reported Value Total
Reported value
$215.4M
Quarter over quarter
+14.9%
Holdings
24
Top-10 concentration
71.1%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Ky Phan
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2026 13F record
Q1 2026 13F filing summary
| Period of report | March 31, 2026 |
|---|---|
| Filed | May 14, 2026 |
| Form | 13F-HR |
| Reported value | $215.4M |
| Positions | 24 |
| Change in reported value | +26.3% |
| New positions | 1 |
| Exited positions | 0 |
| Position turnover | 4.2% |
| Top-10 concentration | 71.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
25 | $234.4M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
22 | $217.4M |
|
Q1 2026 13F
Filed May 14, 2026
|
24 | $215.4M |
|
Q4 2025 13F
Filed Feb 13, 2026
|
23 | $170.5M |
Top 20 holdings · Q1 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | TERN TERNS PHARMACEUTICALS INC | $31.9M | 14.8% |
| 2 | PTGX PROTAGONIST THERAPEUTICS INC | $24.2M | 11.24% |
| 3 | STTK SHATTUCK LABS INC | $20.3M | 9.4% |
| 4 | VOR VOR BIOPHARMA INC | $17.8M | 8.28% |
| 5 | CMPS COMPASS PATHWAYS PLC | $11.2M | 5.19% |
| 6 | RYTM RHYTHM PHARMACEUTICALS INC | $11.0M | 5.09% |
| 7 | XENE XENON PHARMACEUTICALS INC | $10.7M | 4.95% |
| 8 | PVLA PALVELLA THERAPEUTICS INC NE | $10.3M | 4.79% |
| 9 | ZBIO ZENAS BIOPHARMA INC | $8.3M | 3.87% |
| 10 | IVA INVENTIVA SA | $7.4M | 3.44% |
| 11 | VSTM VERASTEM INC | $6.9M | 3.22% |
| 12 | CBIO CRESCENT BIOPHARMA INC. | $6.8M | 3.18% |
| 13 | ORIC ORIC PHARMACEUTICALS INC | $6.6M | 3.08% |
| 14 | GPCR STRUCTURE THERAPEUTICS INC | $6.4M | 2.98% |
| 15 | PCVX VAXCYTE INC | $5.5M | 2.57% |
| 16 | COGT COGENT BIOSCIENCES INC | $5.0M | 2.34% |
| 17 | CMPX COMPASS THERAPEUTICS INC | $4.5M | 2.08% |
| 18 | EVMN EVOMMUNE INC | $4.2M | 1.96% |
| 19 | OCS OCULIS HOLDING AG | $4.0M | 1.85% |
| 20 | ZLAB ZAI LAB LTD | $3.4M | 1.6% |
Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.